Related Experiment Video
Updated: Sep 1, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Multiple myeloma with t(11;14): unique biology and evolving landscape
Susan Bal1, Shaji K Kumar2, Rafael Fonseca3
1Department of Medicine, Division of Hematology Oncology, O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham Birmingham, AL, USA.
Multiple myeloma with the t(11;14) translocation is a distinct subtype characterized by specific biological features and presents a targeted therapy opportunity with BCL-2 inhibition. Further research is needed to clarify its prognostic significance.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma exhibits significant heterogeneity in clinical presentation, treatment response, and patient outcomes.
- The t(11;14) translocation is the most common primary chromosomal abnormality in multiple myeloma, found in 16%-24% of patients.
- This genetic subtype is associated with distinct biological features, including cyclin D1 overexpression, elevated BCL-2 levels, and CD20 expression.
Purpose of the Study:
- To review the unique biology of t(11;14) multiple myeloma.
- To summarize existing literature on the prognosis of patients with t(11;14) multiple myeloma.
- To discuss the therapeutic implications, particularly BCL-2 inhibition, for this patient subset.
Main Methods:
- Literature review and synthesis of existing studies.
- Analysis of biological characteristics of t(11;14) myeloma cells.
- Evaluation of clinical data and prognostic markers.
Main Results:
- t(11;14) multiple myeloma cells display unique molecular profiles, including overexpression of cyclin D1 and BCL-2, and frequent CD20 expression.
- This subtype is associated with less common clinical presentations like immunoglobulin M and light chain disease.
- The prognostic impact of t(11;14) remains under investigation amidst evolving treatment strategies.
Conclusions:
- Multiple myeloma with t(11;14) represents a distinct disease entity with unique biological underpinnings.
- The overexpression of BCL-2 in t(11;14) myeloma offers a potential target for novel therapeutic strategies.
- Further research is warranted to fully elucidate the prognostic value and optimize treatment for t(11;14) multiple myeloma.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Differentiation of Common Myeloid Progenitor Cells
Cancers Originate from Somatic Mutations in a Single Cell

